 The main objective of this study is to demonstrate the safety and effectiveness of the IDev SUPERA Nitinol Stent System in treating subjects with obstructive superficial femoral artery SFA disease. The primary endpoint will be the primary patency of the SFA evaluated at 12 months. The outcome will be compared to a performance goal based on clinical trials of percutaneous transvenous angioplasty PTA alone. 